{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yuan X"],"funding":["METAVivor research","MD Anderson Duncan Family Institute for Cancer Prevention and Risk Assessment NIH Cancer Center Support Grant","NCI NIH HHS","Cancer Prevention Research Institute of Texas","NIH"],"pagination":["1742-1759"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9262841"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(7)"],"pubmed_abstract":["Despite the popular use of dietary supplements during conventional cancer treatments, their impacts on the efficacies of prevalent immunotherapies, including immune-checkpoint therapy (ICT), are unknown. Surprisingly, our analyses of electronic health records revealed that ICT-treated patients with cancer who took vitamin E (VitE) had significantly improved survival. In mouse models, VitE increased ICT antitumor efficacy, which depended on dendritic cells (DC). VitE entered DCs via the SCARB1 receptor and restored tumor-associated DC functionality by directly binding to and inhibiting protein tyrosine phosphatase SHP1, a DC-intrinsic checkpoint. SHP1 inhibition, genetically or by VitE treatment, enhanced tumor antigen cross-presentation by DCs and DC-derived extracellular vesicles (DC-EV),"],"journal":["Cancer discovery"],"pubmed_title":["Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1."],"pmcid":["PMC9262841"],"funding_grant_id":["P30CA016672","R35CA220430","P01CA092584","R01 CA184836","R01CA231149","R35 CA220430","58284","R01 CA231149","R01CA184836","P30 CA016672","RP180813","56675","R01 CA208213","P01 CA092584","R01CA208213"],"pubmed_authors":["Li H","Yuzhalin AE","Sun SC","Yao J","Ahmed Z","Badu-Nkansah A","Saito Y","Xiao Y","Li P","Yu D","Zhang L","Ying H","Kuo WL","Liu X","Tainer JA","Zhang Y","Qi Y","Yuan X","Moiani D","Zhang C","Chang JC","Duan Y","Sun K"],"additional_accession":[]},"is_claimable":false,"name":"Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1.","description":"Despite the popular use of dietary supplements during conventional cancer treatments, their impacts on the efficacies of prevalent immunotherapies, including immune-checkpoint therapy (ICT), are unknown. Surprisingly, our analyses of electronic health records revealed that ICT-treated patients with cancer who took vitamin E (VitE) had significantly improved survival. In mouse models, VitE increased ICT antitumor efficacy, which depended on dendritic cells (DC). VitE entered DCs via the SCARB1 receptor and restored tumor-associated DC functionality by directly binding to and inhibiting protein tyrosine phosphatase SHP1, a DC-intrinsic checkpoint. SHP1 inhibition, genetically or by VitE treatment, enhanced tumor antigen cross-presentation by DCs and DC-derived extracellular vesicles (DC-EV),","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2026-05-09T22:19:05.087Z","creation":"2025-04-06T14:11:17.465Z"},"accession":"S-EPMC9262841","cross_references":{"pubmed":["35420681"],"doi":["10.1158/2159-8290.cd-21-0900","10.1158/2159-8290.CD-21-0900"]}}